Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Robinson

Showing results (121-130 of 167) with videos related to

Pageof 17
Sort By:
Canadian Journal of Kidney Health and Disease|June 28, 2023
Development and Validation of a Predictive Risk Algorithm for Bleeding in Individuals on Long-term Hemodialysis: An International Prospective Cohort Study (BLEED-HD)Mohit Madken, Ranjeeta Mallick, Emily Rhodes, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
Kidney International Reports|December 27, 2021
The Global Impact of the COVID-19 Pandemic on In-Center Hemodialysis Services: An ISN-Dialysis Outcomes Practice Patterns Study SurveyRyan Aylward, Brian Bieber, Murilo Guedes, et al.
Kidney International Reports|August 9, 2022
An ISN-DOPPS Survey of the Global Impact of the COVID-19 Pandemic on Peritoneal Dialysis ServicesRehab Albakr, Brian Bieber, Ryan Aylward, et al.
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
Thyroid : Official Journal of the American Thyroid Association|April 11, 2022
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid CancerJaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Seasonal variations in transition, mortality and kidney transplantation among patients with end-stage renal disease in the USAYoshitsugu Obi, Kamyar Kalantar-Zadeh, Elani Streja, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 16, 2017
Seasonal variations in transition, mortality and kidney transplantation among patients with end-stage renal disease in the USAYoshitsugu Obi, Kamyar Kalantar-Zadeh, Elani Streja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Durability of Response With Selpercatinib in Patients With <i>RET</i>-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.
Journal of the American Society of Nephrology : JASN|July 16, 2025
Genetic Variation and Ultrafiltration with Peritoneal Dialysis: A Genome-Wide Association StudyIan B Stanaway, Ines P D Costa, Simon J Davies, et al.
Pageof 17

Showing results (121-130 of 167) with videos related to

Sort By:
Pageof 17
Canadian Journal of Kidney Health and Disease|June 28, 2023
Development and Validation of a Predictive Risk Algorithm for Bleeding in Individuals on Long-term Hemodialysis: An International Prospective Cohort Study (BLEED-HD)Mohit Madken, Ranjeeta Mallick, Emily Rhodes, et al.
Thyroid : Official Journal of the American Thyroid Association|December 8, 2023
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 StudyJaume Capdevila, Jolanta Krajewska, Jorge Hernando, et al.
Kidney International Reports|December 27, 2021
The Global Impact of the COVID-19 Pandemic on In-Center Hemodialysis Services: An ISN-Dialysis Outcomes Practice Patterns Study SurveyRyan Aylward, Brian Bieber, Murilo Guedes, et al.
Kidney International Reports|August 9, 2022
An ISN-DOPPS Survey of the Global Impact of the COVID-19 Pandemic on Peritoneal Dialysis ServicesRehab Albakr, Brian Bieber, Ryan Aylward, et al.
Frontiers in Oncology|March 20, 2026
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer after prior vascular endothelial growth factor receptor-targeted therapy (COSMIC-311): outcomes by BRAF statusMarcia S Brose, Bhumsuk Keam, Jolanta Krajewska, et al.
Thyroid : Official Journal of the American Thyroid Association|April 11, 2022
A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid CancerJaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 4, 2017
Seasonal variations in transition, mortality and kidney transplantation among patients with end-stage renal disease in the USAYoshitsugu Obi, Kamyar Kalantar-Zadeh, Elani Streja, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 16, 2017
Seasonal variations in transition, mortality and kidney transplantation among patients with end-stage renal disease in the USAYoshitsugu Obi, Kamyar Kalantar-Zadeh, Elani Streja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2024
Durability of Response With Selpercatinib in Patients With <i>RET</i>-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001Lori J Wirth, Marcia S Brose, Vivek Subbiah, et al.
Journal of the American Society of Nephrology : JASN|July 16, 2025
Genetic Variation and Ultrafiltration with Peritoneal Dialysis: A Genome-Wide Association StudyIan B Stanaway, Ines P D Costa, Simon J Davies, et al.
Pageof 17